Company Encyclopedia
View More
name
Bluebird Bio
BLUE.US
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc.
1.902 T
BLUE.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking0/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-546.54%E
    • Profit Margin-192.39%E
    • Gross Margin68.39%A
  • Growth ScoreB
    • Revenue YoY127.51%A
    • Net Profit YoY33.48%B
    • Total Assets YoY-53.13%E
    • Net Assets YoY-144.16%E
  • Cash ScoreB
    • Cash Flow Margin-51.98%D
    • OCF YoY127.51%A
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreE
    • Gearing Ratio119.55%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "AI Darling" Quickly Becomes a "Spendthrift", Can Meta Make a Comeback?

    These days, it's rare to see trillion-dollar giants fluctuating by 10% or 20% in a single day, but Meta is an exception. It took Meta just one quarter to fall from grace. After the Q3 earnings report, investors' panic seemed to have just been digested. Recently, with the expectation of interest rate cuts rising, $Meta Platforms(META.US) has rebounded 10% from the bottom. In terms of narrative, first, Meta has the most extensive application scenarios, and the AI investment process will be accompanied by accelerated revenue, the "AI darling" narrative; then came the Q3 combination of increased investment and slowed revenue growth guidance...

    US
    OWL
    -2.86%
    US
    META
    -1.30%
    HK
    00700
    +2.41%
    US
    OWL
    -2.86%
    US
    META
    -1.30%
    HK
    00700
    +2.41%

    Blue Owl Capital to Present at Goldman Sachs US Financial Services Conference

    Blue Owl Capital Inc. announced that co-CEO Doug Ostrover will present at the Goldman Sachs 2025 US Financial Services Conference on December 10, 2025. The presentation will be webcast live on Blue Owl’s website, with a replay available after the event. This announcement was originally published via PR Newswire.

    Reuters·
    US
    OWL
    -2.86%
    US
    BLUE
    0.00%
    Reuters·
    US
    OWL
    -2.86%
    US
    BLUE
    0.00%

    FULTON FINANCIAL CORPORATION AND BLUE FOUNDRY BANCORP COMBINING IN ALL-STOCK MERGER

    Fulton Financial Corporation and Blue Foundry Bancorp announced an all-stock merger valued at approximately $243 million. Each Blue Foundry share will be exchanged for 0.6500 shares of Fulton. The merger, expected to close in Q2 2026, will expand Fulton's presence in New Jersey and is anticipated to be accretive to earnings and tangible book value. Both companies' boards have approved the merger, pending regulatory and stockholder approvals. Fulton will also contribute $1.5 million to the Fulton Forward Foundation for New Jersey community grants.

    fidelity·
    US
    BLUE
    0.00%
    US
    FULTP
    -0.47%
    fidelity·
    US
    BLUE
    0.00%
    US
    FULTP
    -0.47%

    Financials Flat Amid Volatility Concerns -- Financials Roundup

    Shares of banks and other financial institutions were more or less flat amid concerns about volatility in global markets. Shares of Swedish financial technology firm Klarna fell sharply despite a report of robust quarterly sales growth from the buy-now, pay-later company, which recently floated its shares on public markets. Blue Owl, an investment firm that's among the leading forces on Wall Street in the high-risk private-credit business, recouped some of its recent losses. Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires 11-18-25 1712ET

    marketscreener·
    US
    KLAR
    -3.80%
    US
    BLUE
    0.00%
    US
    OWL
    -2.86%
    marketscreener·
    US
    KLAR
    -3.80%
    US
    BLUE
    0.00%
    US
    OWL
    -2.86%

    Bank of America Securities Reaffirms Their Buy Rating on Blue Owl Capital (OWL)

    Siegenthaler covers the Financial sector, focusing on stocks such as Janus Henderson Group, Blue Owl Capital, and Affiliated Managers. According to TipRanks, Siegenthaler has an average return of 19.9% and a 61.03% success rate on recommended stocks. In addition to Bank of America Securities, Blue Owl Capital also received a Buy from Citizens JMP’s Brian McKenna in a report issued today. However, on October 29, TR | OpenAI – 4o reiterated a Hold rating on Blue Owl Capital (NYSE: OWL).

    Tip Ranks·
    US
    BLUE
    0.00%
    Tip Ranks·
    US
    BLUE
    0.00%
    Posts
    View More

    "Ode to the Hong Kong Stock Market"

    Ten thousand points leap like dragons, a thousand waves surge and fall, tigers roar and dragons howl.

    Watch the red and green dance, yin and yang intertwine; probing ...

    © 2025 Longbridge｜Disclaimer